Drug Target Review – Issue 1 2021

Posted: 25 March 2021 | | No comments yet

In this issue, find articles discussing how high-throughput experimentation can enhance automated molecular discovery, why bNAbs present a promising COVID-19 treatment and how a novel rhinovirus vaccine was developed. Also included are features on immuno-oncology, cell line development and assays. 

Drug Target Review Issue 1 2021

Included in this issue:

    The development of biomaterial-based vaccine platforms against viruses
    Dr Sushma Kumari, Dr Sonal Asthana and Dr Kaushik Chatterjee, Indian Institute of Science
    Which CHO cell is the right CHO cell?
    Dr Louis Boon, Polpharma Biologics Utrecht
    Fighting HIV: could antibodies be the answer?

    Victoria Rees, Drug Target Review
    Expanding accessible chemical space through automated high-throughput experimentation
    Dr Sam Liver, The Rosalind Franklin Institute
    COVID-19 drug targets and cell-based assays
    Sheraz Gul, Fraunhofer Institute and Alp Tegin Sahin, Kadir Has University
    Synthesising very long-chain fatty acids to treat retinal conditions
    Dr Paul Bernstein, University of Utah

The rest of this content is restricted - login or subscribe free to access

Screening the future innovations in drug discoveryThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here